Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study

Inclusion Criteria: * Patient over 18 years of age * Patients with a diagnosis of RA according to ACR/EULAR 2010 criteria * Remission according to DAS28\<=2.6 for at least 6 months * Patient treated with ADA for at least 6 months. The patient is treated according to one of the following two strategies: * ADA 40 mg every two weeks (= every 14 days) according to the standard regimen * or ADA 40 mg every 3 weeks (= every 21 days) * A negative highly sensitive pregnancy test for women of Childbearing Potential\* * Affiliated person or beneficiary of a social security scheme * Informed consent signed by the patient after information Exclusion Criteria: * Incapacity or refusal to understand and / or sign informed consent to participate in the study. * Existing pregnancy, lactation, or intended pregnancy within the next 15 months * Fibromyalgia associated to RA * Any dose of prednisone for RA treatment 6 months before inclusion * Patient deprived of liberty or patient under guardianship or curator ship.